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Lysosomes are cytoplasmic organelles containing  hydrolytic enzymes that 
degrade the macromolecules proteins of cellular catabolism. The causes of 
lysosomal enzyme disorder stem from 
1. Impaired enzyme synthesis
2. Abnormal enzyme targeting
3. Defect of structure of Accessory factor which is needed for enzymes 
function. Clinical manifestations depend on the organ(s) involved.
Seizure disorder, mental handicap and regression are the characteristics of 
many lysosomal enzyme storage diseases. The lysosomal storage disease, as 
first described by Hers are characterized by an accumulation of undergraded 
macromolecules within lysosomes. These disorders are clinically heterogenous 
groups of inborn errors by about 50 different clinical entities. Nature of the 
incompletely degraded macromolecules that accumulate in various tissues 
include:





The acid lipase deficiency diseases 
It is said the combined prevalence of all lysosomal storage disease is 1 in 6600 
to 1 in 7700 live birth (1).
The disease entities result from various single gene mutation with each of 
the enzyme defect is induced by one of the several different abnormalities. 
Mutation or deletions that produce immunologically responsive or unresponsive 
enzyme protein. The defect can impair glycosylation of the enzyme protein or 
cause a failure to generate recognition markers that permits the enzyme to 
attach itself to the lysosomal membrane. The majority of genes that encode 
lysosomal various lysosomal storage disease subtypes is manifested by multi 
systemic involvement. Disease manifestation may be evident prenatally or at 
any time from birth to adulthood on the therapeutic front several modalities 
of treatment have been suggested Enzyme replacement therapy, enzyme 
enhancement therapy, substrate reduction therapy and gene therapy are the 
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different approaches which at present, are being tried.
Treatment of the secondary disabilities like seizure 
disorder, sensory deficit, behavioral problem, and 
sleep-wake cycle disorder has positive impact on the 
patients quality of life and help address some of parental 
anxieties. Genetic counseling of affected individuals 
and their relatives is also important component of care 
of the patient and family.
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